Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity

Journal of Clinical Investigation

Volumn 119, Issue 8, 2009, Pages 2231-2244

  Cubillos Ruiz, Juan R ^a   Engle, Xavier ^a   Scarlett, Uciane K ^a   Martinez, Diana ^a   Barber, Amorette ^a   Elgueta, Raul ^a   Wang, Li ^a   Nesbeth, Yolanda ^a   Durant, Yvon ^b   Gewirtz, Andrew T ^c   Sentman, Charles L ^a   Kedl, Ross ^d   Conejo Garcia, Jose R ^a,e  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEW HAMPSHIRE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e HB 7556 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; GLYCOPROTEIN P 15095; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DIFFERENTIATION FACTOR 88; NANOCOMPOSITE; NANOPARTICLE; OLIGONUCLEOTIDE; POLYETHYLENEIMINE; PROGRAMMED CELL DEATH 1 LIGAND 1; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INFILTRATION; CANCER REGRESSION; CANCER SURVIVAL; CELL TRANSFORMATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NANOENCAPSULATION; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR GENE; RECEPTOR UPREGULATION; TLR5 GENE; TUMOR IMMUNITY;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD80; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; NANOPARTICLES; OVARIAN NEOPLASMS; PEPTIDES; POLYETHYLENEIMINE; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 5;

EID: 68849112640     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37716     Document Type: Article

References (52)

1. Jemal, A., et al. 2008. Cancer statistics, 2008. CA Cancer J. Clin. 58:71-96.
2. Coukos, G., Conejo-Garcia, J.R., Buckanovich, R., and Benencia, F. 2007. Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Adv. Exp. Med. Biol. 590:185-193.
3. Curiel, T.J., et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562-567.
4. Gabrilovich, D.I., et al. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67:425; author reply 426.
5. Plate, J.M., and Harris, J.E. 2000. Immune cell functions in pancreatic cancer. Crit. Rev. Immunol. 20:375-392.
6. Curiel, T.J., et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-949.
7. Keir, M.E., Butte, M.J., Freeman, G.J., and Sharpe, A.H. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677-704.
8. Bak, S.P., Walters, J.J., Takeya, M., Conejo-Garcia, J.R., and Berwin, B.L. 2007. Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res. 67:4783-4789.
9. Conejo-Garcia, J.R., et al. 2004. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 10:950-958.
10. Conejo-Garcia, J.R., et al. 2005. Vascular leukocytes contribute to tumor vascularization. Blood. 105:679-681.
11. Coukos, G., Benencia, F., Buckanovich, R.J., and Conejo-Garcia, J.R. 2005. The role of dendritic cell precursors in tumour vasculogenesis. Br. J. Cancer. 92:1182-1187.
12. Coukos, G., Conejo-Garcia, J.R., Roden, R.B., and Wu, T.C. 2005. Immunotherapy for gynaecological malignancies. Expert Opin. Biol. Ther. 5:1193-1210.
13. Huarte, E., et al. 2008. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res. 68:7684-7691.
14. Zhang, L., et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:203-213.
15. Conejo-Garcia, J.R., et al. 2004. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer Res. 64:2175-2182.
16. Hornung, V., et al. 2005. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11:263-270.
17. Kleinman, M.E., et al. 2008. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 452:591-597.
18. Rossi, J., Zamore, P., and Kay, M.A. 2008. Wandering eye for RNAi. Nat. Med. 14:611.
19. Marques, J.T., and Williams, B.R. 2005. Activation of the mammalian immune system by siRNAs. Nat. Biotechnol. 23:1399-1405.
20. Judge, A.D., et al. 2005. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23:457-462.
21. Hwang, J.Y., et al. 2008. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 68:5849-5858.
22. Merritt, W.M., et al. 2008. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl. Cancer Inst. 100:359-372.
23. Landen, C.N., Jr., et al. 2005. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65:6910-6918.
24. Song, E., et al. 2003. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J. Virol. 77:7174-7181.
25. Grzelinski, M., et al. 2006. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17:751-766.
26. Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., and Aigner, A. 2005. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12:461-466.
27. Stary, G., et al. 2007. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204:1441-1451.
28. Roux, S., et al. 2008. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J. Clin. Invest. 118:3751-3761.
29. Gorden, K.B., et al. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174:1259- 1268.
30. Vijay-Kumar, M., et al. 2008. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J. Immunol. 180:8280-8285.
31. Hung, C.F., Tsai, Y.C., He, L., and Wu, T.C. 2007. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther. 14:921-929.
32. Di Rosa, F., and Pabst, R. 2005. The bone marrow: a nest for migratory memory T cells. Trends Immunol. 26:360-366.
33. Parretta, E., et al. 2005. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J. Immunol. 174:7654-7664.
34. Poeck, H., et al. 2008. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14:1256-1263.
35. Louis, M.H., et al. 2006. Intraperitoneal linear polyethylenimine (L-PEI)-mediated gene delivery to ovarian carcinoma nodes in mice. Cancer Gene Ther. 13:367-374.
36. Zou, S.M., Erbacher, P., Remy, J.S., and Behr, J.P. 2000. Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse. J. Gene Med. 2:128-134.
37. Taieb, J., et al. 2006. A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 12:214-219.
38. Chan, C.W., et al. 2006. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12:207-213.
39. Vosshenrich, C.A., et al. 2007. CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J. Exp. Med. 204:2569-2578.
40. Saudemont, A., and Quesnel, B. 2004. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood. 104:2124-2133.
41. Wei, S., et al. 2008. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res. 68:5432-5438.
42. Ramakrishna, V., et al. 2003. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int. Immunol. 15:751-763.
43. Yen, M.J., et al. 2006. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin. Cancer Res. 12:827-831.
44. Odunsi, K., et al. 2003. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 63:6076-6083.
45. Hasegawa, K., et al. 2004. SSX expression in gynecological cancers and antibody response in patients. Cancer Immun. 4:16.
46. Kershaw, M.H., et al. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12:6106-6115.
47. Uematsu, S., et al. 2006. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat. Immunol. 7:868-874.
48. Barber, M.A., Zhang, T., Gagne, B.A., and Sentman, C.L. 2007. NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model. J. Immunol. 178:6140-6147.
49. Yamazaki, T., et al. 2002. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169:5538-5545.
50. Tsushima, F., et al. 2003. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur. J. Immunol. 33:2773-2782.
51. Tsushima, F., et al. 2006. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 42:268-274.
52. Barber, A., et al. 2007. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 67:5003-5008.